Delivery of the Report will take 2-3 working days once order is placed.
Synopsis
Chronic idiopathic constipation (CIC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. The term idiopathic is used because it means there is no known cause. CIC includes symptoms of difficult, infrequent, or incomplete bowel movements.
Scope of the Report:
The worldwide market for Chronic Idiopathic Constipation (CIC) Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
This report focuses on the Chronic Idiopathic Constipation (CIC) Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Actavis
- Chugai Pharmaceutical
- Ferring International Center
- Synergy Pharmaceuticals
- Pfizer
- GlaxoSmithKline
- Roche Holding
- Sanofi
- Bayer
- Salix Pharmaceuticals
- Sucampo Pharmaceuticals
- Ironwood Pharmaceuticals
- Progenics Pharmaceuticals
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Lubiprostone
- Linaclotide
- Others
Market Segment by Applications, can be divided into
- Hospitals & Clinics
- Ambulatory Surgical Centres
- Long Term Care Centres
- Others
There are 15 Chapters to deeply display the global Chronic Idiopathic Constipation (CIC) Drugs market.
Chapter 1, to describe Chronic Idiopathic Constipation (CIC) Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Chronic Idiopathic Constipation (CIC) Drugs, with sales, revenue, and price of Chronic Idiopathic Constipation (CIC) Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Chronic Idiopathic Constipation (CIC) Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Chronic Idiopathic Constipation (CIC) Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Chronic Idiopathic Constipation (CIC) Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source